FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Viatris Levsin injection Recall

Levsin injection (hyoscyamine sulfate injection, USP), 0

Viatris Inc · Canonsburg, PA

Risk level
Class II
Reported by FDA
Jun 14, 2023
Recall ID
D-0866-2023
Check your lot numberHow we source this data

Summary

Viatris recalled Levsin injection starting May 25, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0866-2023 on Jun 14, 2023. Reason: CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess. Status: Terminated.

Why it was recalled

CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

Product description

Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml Ampule (Box of 5 ampules), Rx Only, Distributed by: Meda pharmaceuticals Inc. (a Viatris company) Somerset New Jersey 00873-4120, NDC #0037-9001-05

Lot numbers, UPCs & expiration codes

Lot #: 101241A, Exp 10/23

Where it was sold

Product was distributed to 10 distributors who may have further distribute the product to the retail level.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0866-2023
Classification
Class II
Status
Terminated
Recall initiated
May 25, 2023
FDA report date
Jun 14, 2023
Quantity
2,736 boxes
Recall type
Voluntary: Firm initiated
Recalling firm
Viatris Inc

Original FDA data

Every field from FDA enforcement report D-0866-2023, exactly as published.

Show all FDA fields
City
Canonsburg
State
PA
Status
Terminated
Country
United States
Event ID
92366
Address
1000 Mylan Blvd
Code information
Lot #: 101241A, Exp 10/23
Postal code
15317-5853
Report date
Jun 14, 2023
Product type
Drugs
Recall number
D-0866-2023
Classification
Class II
Recalling firm
Viatris Inc
Product quantity
2,736 boxes
Termination date
Apr 11, 2024
Reason for recall
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Levsin injection (hyoscyamine sulfate injection, USP), 0.5 mg per ml in water for Injection, 1 ml Ampule (Box of 5 ampules), Rx Only, Distributed by: Meda pharmaceuticals Inc. (a Viatris company) Somerset New Jersey 00873-4120, NDC #0037-9001-05
Distribution pattern
Product was distributed to 10 distributors who may have further distribute the product to the retail level.
Recall initiation date
May 25, 2023
Initial firm notification
Letter
Center classification date
Jun 5, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0866-2023, published Jun 14, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls